Max Hodak

Founder and CEO

Therapeutic Areas

Drug	Indication	Phase
PRIMA Retinal Implant	Geographic Atrophy secondary to Age-Related Macular Degeneration (Vision Restoration)	Phase 2/3
Biohybrid Neural Interface Platform	Neurological Disorders (Broad BCI Applications)	Research/Pre-clinical
Vessel Perfusion System	Organ Perfusion & Preservation	Research